Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586244 · ClinicalTrials.gov registry record · Phase 2
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04586244 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 30 participants.
The verdict
NCT04586244, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.
Interventions
- DRUG INCAGN02385
- DRUG INCAGN02390
- DRUG retifanlimab
- DRUG epacadostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-14 |
| Est. Completion | 2024-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04586244
The ClinicalTrials.gov registry entry for NCT04586244 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which INCAGN02385 is the first listed.
NCT04586244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04586244 about?
NCT04586244 is a clinical study titled "An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma". This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.
What is the current status of trial NCT04586244?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-01-14. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT04586244?
The interventions under investigation include: INCAGN02385 (DRUG), INCAGN02390 (DRUG), retifanlimab (DRUG), epacadostat (DRUG).
Who is sponsoring clinical trial NCT04586244?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.